PERSONAL INFORMATION

i2o Therapeutics is pioneering the use of Ionic Liquids (ILs) for therapeutic development. i2o's wholly-owned pipeline consists of first-in-class and best-in-class transformative oral biologics with improved clinical benefits and a superior safety profile over current standard of care. With an initial focus on metabolic and inflammatory diseases, i2o is delivering on the promise of oral biologics-considered the "holy grail biologic opportunity" by the pharmaceutical industry.

Primary location: Cambridge United States